Robeco Institutional Asset Management B.V. lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 84.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 55,074 shares of the medical research company’s stock after selling 308,028 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Amgen were worth $9,484,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in AMGN. Signature Estate & Investment Advisors LLC lifted its position in Amgen by 13.6% during the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock valued at $130,000 after buying an additional 95 shares during the period. Jackson Grant Investment Advisers Inc. lifted its position in Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the period. Capital One National Association lifted its position in Amgen by 0.5% during the first quarter. Capital One National Association now owns 16,690 shares of the medical research company’s stock valued at $2,738,000 after buying an additional 90 shares during the period. Cypress Capital Management LLC lifted its position in Amgen by 49.7% during the first quarter. Cypress Capital Management LLC now owns 3,360 shares of the medical research company’s stock valued at $551,000 after buying an additional 1,115 shares during the period. Finally, Rhumbline Advisers lifted its position in Amgen by 1.4% during the first quarter. Rhumbline Advisers now owns 1,314,521 shares of the medical research company’s stock valued at $215,673,000 after buying an additional 18,213 shares during the period. 78.54% of the stock is owned by hedge funds and other institutional investors.
Amgen Inc. (AMGN) opened at $172.35 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. The stock has a market capitalization of $125,110.77, a PE ratio of 13.70, a P/E/G ratio of 2.50 and a beta of 1.37. Amgen Inc. has a 1 year low of $138.83 and a 1 year high of $191.10.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The company’s revenue was down .7% on a year-over-year basis. During the same period in the prior year, the company earned $3.02 earnings per share. equities analysts predict that Amgen Inc. will post 12.66 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be issued a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.67%. The ex-dividend date of this dividend is Thursday, November 16th. Amgen’s dividend payout ratio (DPR) is 41.63%.
Amgen declared that its board has authorized a stock repurchase plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.
Several equities analysts have recently weighed in on AMGN shares. Cann restated a “buy” rating and set a $203.00 price target (up from $189.00) on shares of Amgen in a report on Wednesday, July 26th. Jefferies Group LLC reiterated a “buy” rating and issued a $195.00 price objective on shares of Amgen in a report on Monday, July 17th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $203.00 price objective on shares of Amgen in a report on Thursday, September 7th. Mizuho reiterated a “buy” rating and issued a $183.00 price objective (down from $195.00) on shares of Amgen in a report on Monday, August 21st. Finally, BidaskClub downgraded Amgen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Thirteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Amgen presently has an average rating of “Buy” and an average target price of $190.03.
In other Amgen news, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here. 0.19% of the stock is owned by company insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.